MM-111

DB17983InvestigationalProtein Based Therapies

MM-111 is a novel bispecific antibody fusion protein that co-targets the the epidermal growth factor family receptor tyrosine kinases, ERBB2 and ERBB3.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2 and Receptor tyrosine-protein kinase erbB-3
Curator reviewed
Also known as: Antibody bispecific for erbb2 and erbb3 · Bispecific her2/her3 antibody albumin fusion protein
Code names: MM-111

Resolves to

Compound

UNII6IJ4CQY76OCAS1361108-53-3

Targets

P04626ERBB2P21860ERBB3

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with MM-111, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account